Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Feb 29, 2024 11:21am
86 Views
Post# 35906586

PLWH if you want to live longer start with right medicine

PLWH if you want to live longer start with right medicine

 

The obesity related metabolic diseases should be the primary concern when patients are initiated on the weight loss drugs. Poor/cheap calorigenic food high in carbohydrates and fat are the most common causes of obesity and obesity related health problems. 

This study was performed on rats nevertheless their findings suggest a significant correlation between obesogenic low protein high calorie food combined with anti viral HIV drugs and increased metabolic syndrome related mortality.  However Tesamorelin reversed the metabolic issues when co-administrated with cARTs. So PLWH who often gain weight in the first few years ofter they have been treated with antivirals should avoid low protein high calorie diets which is easier said than done failing the dietary approach they should get started on Tesamorelin to avoid deadly metabolic disease. It might look good to conveniently shed few pounds by taking obesity drugs but you will live longer if you get started on Tesamorelin.

 

"This study showed that the low protein high calorie diet was obesogenic. These obesogenic activities were as great as /exceeded that of the classical cafeteria diet (normal protein high calorie diet) in addition this lowprotein high calorie diet interacted with both IICR and classical cART drug regimen to reproduce cART associated metabolic dysregulations. These dysregulations were however reversed by co-treatment with tesamorelin indicating the possible involvement of the growth hormone system dysfunction in its pathophysiology.

The finding from this study therefore may provide a potential pathophysiologic explanation for the observed increased mortality rate seen in sub-Saharan Africa when cART is initiated in patients with nutritional insufficiency."

 

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0298752

<< Previous
Bullboard Posts
Next >>